Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon β-1B

Neurology

Volumn 52, Issue 2, 1999, Pages 351-359

  Kastrukoff, Lorne F ^a   Morgan, N G ^a   Zecchini, D ^a   White, R ^a   Petkau, A J ^a   Satoh, J ^b   Paty, D W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD57 ANTIGEN; CHROMIUM 51; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TARGET CELL;

EID: 0033556415     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.2.351     Document Type: Article

References (50)

1. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebocontrolled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:662-667.
3. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994;17:1-53.
4. Riechmann P. The effects of interferon-β on cytokines and immune responses. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:161-191.
5. Benczur M, Pentranyl GG, Palffy G, et al. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol 1980;39:657-662.
6. Merrill J, Jondal M, Seeley J, Ullberg M, Siden A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of the disease. Clin Exp Immunol 1982;47:419-430.
7. Neighbour PA, Grayzel AI, Miller AE. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol 1982;49:11-21.
8. Hirsch RL, Johnson KP. Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-α2. Clin Immunol Immunopathol 1985;37:236-244.
9. Kastrukoff LF, Morgan NG, Aziz TM, Zecchini D, Berkowitz J, Paty DW. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid Interferon. J Neuroimmunol 1988;20:15-23.
10. Hauser SL, Ault KA, Levin MJ, Garovoy MR, Weiner HL. Natural killer cell activity in multiple sclerosis. J Immunol 1981;127:1114-1117.
11. Santoli D, Hall W, Kastrukoff LF, et al. Cytotoxic activity and Interferon production by lymphocytes from patients with multiple sclerosis. J Immunol 1981;126:1274-1278.
12. Rice GPA, Casali P, Merigan TC, Oldstone BA. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann Neurol 1983;14:333-338.
13. Oger J, Kastrukoff LF, O'Gorman M, Paty DW. Progressive multiple sclerosis: abnormal immune factors in vitro and aberrant correlation with enumeration of lymphocyte subpopula-tions. J Neuroimmunol 1986;12:37-48.
14. Kastrukoff LF, Morgan N, Zecchini D, et al. A role for natural killer (NK) cells in the immunopathogenesis of multiple sclerosis (MS). J Neuroimmunol 1998;86:123-133.
15. Nestaas E, Files JG, Nelson JW, Pungor E Jr. Quantitation and characterization of multiple sclerosis patient antibodies to interferon-β. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:523-530.
16. Liang KY, Zeger SL. Longitudinal data analysis using gener-alized linear models. Biometrika 1986;73:13-22.
17. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
18. Knobler RL. Interferon β-1b (Betaseron) treatment of multiple sclerosis. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:353-413.
19. Herndon RM. Interferon β-1a treatment of multiple sclerosis. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:343-352.
20. Pfeffer LM, Constantinescu SN. The molecular biology of interferon-β from receptor binding to transmembrane signaling. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:1-40.
21. Decker T. The molecular biology of type I interferons (interferon-α/β) (Gene activation, promoters, proteins induced). In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:41-76.
22. Dianzani F, Antonelli G. Physiological mechanism of production and action of interferons in response to viral infections. Adv Exp Med Biol 1989;257:47-60.
23. Taylor JL, Grossberg SE. Recent progress in Interferon research: molecular mechanism of regulation, action and virus circumvention. Virus Res 1990;15:1-26.
24. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant Interferon beta. Neurology 1993;43:2080-2087.
25. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
26. Panitch HS, Folus JS, Johnson KP. Recombinant beta interferon inhibits gamma Interferon production in multiple sclerosis. Ann Neurol 1987;22:139-143.
27. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207-210.
28. Arnason BGW. Short analytical review: interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996;81: 1-11.
29. 2-interferon on defective natural killer cell activity in multiple sclerosis. Neurology 1985;35:597-600.
30. Hirsch RL, Johnson KP. Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-α2. Clin Immunol Immunopathol 1985;37:236-244.
31. Whiteside TL, Herberman RB. The role of natural killer cells in human disease. Clin Immunol Immunopathol 1989;53: 1-23.
32. Lanier LL, Le M, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu 11) and Leu 19 (NKH-antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4487.
33. Nagao F, Yabe T, Xu M, Okumura K. Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations. Nat Immunol 1995;14:225-233.
34. Santoli D, Trinchierei G, Moretta L, Zmijewski CM, Koprowski H. Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol 1978;33:309-318.
35. Nagler A, Lanier LL, Cwiela S, Phillips JH. Comparative studies of human FcRIII-positive and negative NK cells. J Immunol 1989;143:3183-3189.
36. Knapp W, Rieber P, Dorken B, Schmidt RE, Stein H, Borne AEGKrvd. Towards a better definition of human leukocyte surface molecules. Immunol Today 1989;10:253-258.
37. Galatiuc C, Gherman M, Metes D, et al. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies. Cell Immunol 1995;163:167-177.
38. Lanier LL, Phillips JH. Evidence for three types of human cytotoxic lymphocytes. Immunol Today 1986;7:132-134.
39. + T lymphocytes that express Fc receptors for IgG (CD16/Leu 11 antigens). J Exp Med 1985; 162:2089-2106.
40. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared with control subjects. J Neuroimmunol 1995;62:177-181.
41. Abo T, Balch BM. A differentiation antigen of human NK cells and K cells identified by a monoclonal antibody (HNK-1). J Immunol 1981;127:1024-1029.
42. Lanier LL, Le AM, Phillips JH, Warner NL, Babock GF. Populations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983;131:1789-1796.
43. Lanier LL, Engleman EG, Gatenby P, Babcock GF, Warner NL, Herzenberg LA. Correlation of functional properties of human lymphoid cell subsets and surface marker phenotypes using multiparameter analysis and flow cytometry. Immunol Rev 1983;74:143-160.
44. bright+ natural killer cell subpopulations. Int Arch Allergy Immunol 1996;110:308-313.
45. Warren HS. NK cell proliferation and inflammation. Immunol Cell Biol 1996;74:473-480.
46. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Invest 1992; 70:539-544.
47. Whiteside TL, Herbermann RB. Role of human natural killer cells in health and disease. Clin Diagn Lab Immunol 1994;1: 125-133.
48. Weber WEJ, Buurman WA, Vandermeeren RHJ, Medaer MD, Faus JCM. Fine analysis of cytolytic and natural killer T lymphocytes in the CSF in multiple sclerosis and other neurologic diseases. Neurology 1987;37:419-425.
49. Traugott U. Characterization and distribution of lymphocyte subpopulations in multiple sclerosis plaques versus autoimmune demyelinating lesions. Semin Immunopathol 1984;8: 71-95.
50. Antel J, McCrea E, Ladiwala U, Qin Y, Becher B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J Immunol 1998;160: 1606-1611.